FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

By B. Mann, John R. Johnson, M. Cohen, R. Justice, R. Pazdur. The Oncologist, 2007

1,291 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Metabolic reprogramming and epigenetic modifications on the path to cancer (2021, background): “…Drug Administration (FDA)-approved acetylating modifier, vorinostat (also known as suberanilohydroxamic acid (SAHA)), was initially identified as a drug that induces tumor cell differentiation in vitro and was subsequently identified as an HDAC inhibitor (Richon et al., 1998; Mann et al., 2007).”
HDACs and HDAC Inhibitors in Cancer Development and Therapy (2016, neutral): “Vorinostat (SAHA) Classes I, II, and IV CTCL FDA approved in 2006 Mann et al. 2007 Belinostat (Beleodaq/ PXD101) Classes I, II, and IV PTCL FDA approved in 2014 McDermott and Jimeno 2014 Panobinostat (LBH-589) Classes I, II, and IV MM FDA approved in 2015 Richardson et al. 2015 Resminostat…”
FOXP3+ regulatory T cells in the human immune system (2010, background): “The drug is in clinical use for the management of cutaneous T cell lymphoma but it remains to be determined whether it can have a T Reg cell-specific effect in vivo”
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, background): “The objective response rate determined by direct evidence of clinical benefit was 30% [26].”